Tumor-targeted delivery of a STING agonist improves cancer immunotherapy

99Citations
Citations of this article
83Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The cGAS-STING pathway is essential for immune defense against microbial pathogens and malignant cells; as such, STING is an attractive target for cancer immunotherapy. However, systemic administration of STING agonists poses safety issues while intratumoral injection is limited by tumor accessibility. Here, we generated antibody-drug conjugates (ADCs) by conjugating a STING agonist through a cleavable linker to antibodies targeting tumor cells. Systemic administration of these ADCs was well tolerated and exhibited potent antitumor efficacy in syngeneic mouse tumor models. The STING ADC further synergized with an anti-PD-L1 antibody to achieve superior antitumor efficacy. The STING ADC promoted multiple aspects of innate and adaptive antitumor immune responses, including activation of dendritic cells, T cells, natural killer cells and natural killer T cells, as well as promotion of M2 to M1 polarization of tumor-associated macrophages. These results provided the proof of concept for clinical development of the STING ADCs.

Author supplied keywords

Cite

CITATION STYLE

APA

Wu, Y. T., Fang, Y., Wei, Q., Shi, H., Tan, H., Deng, Y., … Chen, Z. J. (2022). Tumor-targeted delivery of a STING agonist improves cancer immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 119(49). https://doi.org/10.1073/pnas.2214278119

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free